Trials / Completed
CompletedNCT03832738
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTE-451 Tablets | Active drug tablets containing JTE-451 |
| DRUG | Placebo Tablets | Placebo tablets matching in appearance to the active drug tablets |
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2020-03-13
- Completion
- 2020-03-13
- First posted
- 2019-02-06
- Last updated
- 2021-08-20
- Results posted
- 2021-08-16
Locations
33 sites across 3 countries: United States, Canada, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03832738. Inclusion in this directory is not an endorsement.